OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
337357

Radiant Innovation Inc

Medical Equipment, Supplies & DistributionVerified

Radiant Innovation Inc has a strong liquidity position, with a current ratio of 9.69 and no long-term debt, indicating a robust balance sheet with minimal leverage. The company holds TWD 134.75 million in cash and equivalents, which is a significant portion of its total assets of TWD 861.31 million. However, the company reported negative operating income of TWD -70.36 million and net income of TWD -60.45 million, reflecting a challenging operating environment. The company's profitability metrics are below industry norms, with a return on equity (ROE) of -7.61% and a return on assets (ROA) of -7.02%. These figures suggest that the company is not generating returns that meet the cost of capital or industry expectations. Gross profit of TWD 60.01 million on revenue of TWD 387.58 million indicates a gross margin of approximately 15.5%, which is relatively low for a medical equipment manufacturer. Radiant Innovation Inc's revenue is primarily derived from the sale of medical devices and equipment, with a focus on infrared temperature measurement instruments and related components. The company distributes its products in the domestic market and to overseas markets, including the rest of Asia, the Americas, and Europe. However, the input data does not provide specific revenue breakdowns by segment or geography, limiting the ability to assess concentration risk. The company's growth trajectory is uncertain, as the input data does not include forward-looking revenue projections or historical growth rates. The negative net income and operating income suggest that the company is currently facing operational challenges, which could impact its ability to grow revenue in the near term. The company's free cash flow is negative at TWD -45.71 million, indicating that it is not generating sufficient cash from operations to fund its capital expenditures of TWD -8.04 million. The risk assessment for Radiant Innovation Inc indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's strong cash position and absence of long-term debt contribute to its low liquidity risk. However, the negative operating and net income suggest that the company may face financial challenges in the future, which could increase its risk profile. Recent events and filings for Radiant Innovation Inc are not detailed in the input data, so there is no information available on recent strategic moves, product launches, or regulatory changes that could impact the company's performance. The absence of such information limits the ability to assess the company's recent operational and financial developments.

30-day price · 3373-0.25 (-1.4%)
Low$16.60High$17.80Close$17.05As of21 May, 00:00 UTC
Profile
CompanyRadiant Innovation Inc
Ticker3373.TWO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Radiant Innovation Inc is a Taiwan-based company engaged in the research, development, manufacture, and sales of medical devices and equipment, including infrared temperature measurement instruments, CO₂ detectors, and blood glucose chipsets.

Classification. Radiant Innovation Inc is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Radiant Innovation Inc has a strong liquidity position, with a current ratio of 9.69 and no long-term debt, indicating a robust balance sheet with minimal leverage. The company holds TWD 134.75 million in cash and equivalents, which is a significant portion of its total assets of TWD 861.31 million. However, the company reported negative operating income of TWD -70.36 million and net income of TWD -60.45 million, reflecting a challenging operating environment. The company's profitability metrics are below industry norms, with a return on equity (ROE) of -7.61% and a return on assets (ROA) of -7.02%. These figures suggest that the company is not generating returns that meet the cost of capital or industry expectations. Gross profit of TWD 60.01 million on revenue of TWD 387.58 million indicates a gross margin of approximately 15.5%, which is relatively low for a medical equipment manufacturer. Radiant Innovation Inc's revenue is primarily derived from the sale of medical devices and equipment, with a focus on infrared temperature measurement instruments and related components. The company distributes its products in the domestic market and to overseas markets, including the rest of Asia, the Americas, and Europe. However, the input data does not provide specific revenue breakdowns by segment or geography, limiting the ability to assess concentration risk. The company's growth trajectory is uncertain, as the input data does not include forward-looking revenue projections or historical growth rates. The negative net income and operating income suggest that the company is currently facing operational challenges, which could impact its ability to grow revenue in the near term. The company's free cash flow is negative at TWD -45.71 million, indicating that it is not generating sufficient cash from operations to fund its capital expenditures of TWD -8.04 million. The risk assessment for Radiant Innovation Inc indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's strong cash position and absence of long-term debt contribute to its low liquidity risk. However, the negative operating and net income suggest that the company may face financial challenges in the future, which could increase its risk profile. Recent events and filings for Radiant Innovation Inc are not detailed in the input data, so there is no information available on recent strategic moves, product launches, or regulatory changes that could impact the company's performance. The absence of such information limits the ability to assess the company's recent operational and financial developments.
Key takeaways
  • Radiant Innovation Inc has a strong liquidity position with a current ratio of 9.69 and no long-term debt.
  • The company is currently unprofitable, with a return on equity of -7.61% and a return on assets of -7.02%.
  • The company's revenue is derived from the sale of medical devices and equipment, with a focus on infrared temperature measurement instruments.
  • The company's growth trajectory is uncertain, with negative net income and operating income.
  • The risk assessment indicates low liquidity and dilution risk, but the company's financial performance suggests potential future challenges.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$387.6M
Gross profit$60.0M
Operating income-$70.4M
Net income-$60.4M
R&D
SG&A
D&A
SBC
Operating cash flow$2.8M
CapEx-$8.0M
Free cash flow-$45.7M
Total assets$861.3M
Total liabilities$67.5M
Total equity$793.8M
Cash & equivalents$134.7M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$793.8M
Net cash$134.7M
Current ratio9.7
Debt/Equity0.0
ROA-7.0%
ROE-7.6%
Cash conversion-5.0%
CapEx/Revenue-2.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric3373Activity
Op margin-18.2%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-15.6%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin15.5%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-2.1%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity0.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 12:15 UTC#9daa392a
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 19:47 UTCJob: a03f8747